DAB.bio, a burgeoning biotechnology company rooted in Delft, has recently secured fresh investment from Navus Ventures and Capricorn Partners, aimed at enhancing the reach and scope of its continuous fermentation technology. This strategic financial backing is expected to propel DAB.bio’s pioneering FAST platform through its next commercial phase, equipping partners with advanced capabilities for large-scale fermentation. With sustainability at its core, this funding further aligns with the investors’ commitment to advancing sustainable food and energy solutions.
Historically, DAB.bio has been recognized for its innovative approach to fermentation technology, which allows for an efficient and cost-effective production process. In 2022, previous reports highlighted the company’s gradual ascension within the biotechnology sector by focusing on the scalable and versatile applications of its FAST technology. The newly acquired investment resonates with the ongoing narrative of DAB.bio’s commitment to pushing the boundaries of industrial fermentation.
What is the focus of DAB.bio’s newly secured investment?
The focus of the recent investment is the FAST platform by DAB.bio, which emphasizes a more efficient fermentation process. FAST is designed to lower the costs and enhance efficiency compared to traditional methods, thus creating an appealing prospect for partners requiring robust production solutions. This advancement not only promises large-scale implementation but also reflects the company’s dedication to offering a sustainable biomanufacturing alternative.
Why did Navus Ventures and Capricorn Partners invest in DAB.bio?
Navus Ventures, known for investing in high-tech startups, finds DAB.bio’s FAST platform aligned with its strategy towards sustainability. According to Olivier van Holthe tot Echten from Navus Ventures, this investment is seen as an exciting addition to their portfolio. Capricorn Partners echo this sentiment, viewing DAB.bio as a key player in the shift towards a biobased economy. They aim to facilitate the commercial growth of this platform by bolstering its technological advancement.
Subsequent to the funding round, DAB.bio plans to pave the way for a Series A funding round, signaling robust development and growth potential. The company’s CEO, Eric van der Meer, expressed contentment with the new financial influx, acknowledging the challenges present in the industrial biotechnology market.
“We are extremely pleased with the support from our new and existing investors,” stated van der Meer, while emphasizing the market challenges and affirming the investment as a favorable endorsement.
As DAB.bio looks to capitalize on the investment, it aims to deploy its first full-scale commercial application, aiming to secure a strong foothold in the European biotechnology landscape and beyond. The company’s vision entails establishing itself as a significant player in the global market.
“We have a strong pipeline,” van der Meer added, highlighting the technological and commercial roadmap they have outlined.
The investment is not only a testament to the potential of DAB.bio’s FAST platform but also a reflection of the growing interest in sustainable industrial biotechnology solutions. With continued support and strategic partnerships, DAB.bio stands poised to make significant advancements in the field.
